ClinicalTrials.gg
Not yet recruitingNCT07941245CLEAR-NEOUpdated Nov 18, 2026

Prevalence of Neonatal Delirium

An observational study in Neonatal Delirium, sponsored by Copenhagen University Hospital, Rigshospitalet. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Copenhagen University Hospital, Rigshospitalet · Observational

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
500
Sex
All
01

Study summary

The CLEAR-NEO study is an international multicenter observational study designed to estimate the prevalence of neonatal delirium among critically ill neonates admitted to neonatal intensive care units (NICUs). Participating NICUs will perform standardized delirium assessments using the Cornell Assessment of Pediatric Delirium (CAPD) on three designated study days. The study aims to determine the point prevalence of neonatal delirium.

Read the detailed description

Neonatal delirium is increasingly recognized as a neurocognitive complication of critical illness, but knowledge regarding its prevalence in neonatal intensive care units (NICUs) remains limited. Existing studies have been small, single-center investigations, and reported prevalence estimates vary considerably. Large international epidemiological studies of neonatal delirium have not previously been conducted.

The International Clinical Epidemiology and Assessment of prevalence Rates of delirium in NEOnates (CLEAR-NEO) study is an international multicenter observational point prevalence study designed to estimate the prevalence of neonatal delirium among critically ill neonates admitted to NICUs. Participating sites will be recruited internationally through neonatal and pediatric critical care research networks and professional organizations.

On three predefined study days, eligible neonates with a postmenstrual age of 34+0 to 44+0 weeks who have been admitted to a participating NICU for at least 48 hours will undergo delirium assessment using the Cornell Assessment of Pediatric Delirium (CAPD). Neonates will be classified as delirium-positive when at least one CAPD assessment performed on the study day yields a score of 9 or higher.

In addition to delirium assessments, participating sites will provide aggregated data regarding patient characteristics, clinical variables, and NICU characteristics. No patient-identifiable information or individual patient-level data will be transferred to the coordinating center. Data will be entered into a secure REDCap database hosted by Copenhagen University Hospital Rigshospitalet.

The primary objective is to estimate the international point prevalence of neonatal delirium among critically ill neonates admitted to NICUs. Secondary objectives include describing delirium subtypes and characterizing participating NICUs and patient populations.

02

Conditions studied

  • Neonatal Delirium

Browse trials for

Keywords

  • Neonatal delirium
  • Delirium
  • Neonate
  • Neonatal Intensive Care Unit
  • NICU
  • Cornell Assessment of Pediatric Delirium
  • CAPD
  • Point prevalence study
03

In context

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

This study's planned enrollment of 500 is above the median of 196 across 343 observational studies indexed under Delirium.

Browse Delirium studies →

Lead sponsor

Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 46 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Neonates admitted to participating neonatal intensive care units (NICUs). Eligible participants have a postmenstrual age of 34+0 to 44+0 weeks and have been admitted to the NICU for at least 48 hours at the time of assessment. Participating sites are recruited internationally and include NICUs of different levels of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postmenstrual age 34+0 to 44+0 weeks
  • Admitted to a participating NICU for at least 48 hours at 8:00 AM local time on the study day
  • Present in the NICU on the designated study day

Exclusion criteria

Exclusion Criteria:

  • Deep sedation (Richmond Agitation Sedation Scale ≤ -4)
  • Pharmacological paralysis
  • Receiving comfort care only
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Eligible Neonates

    Neonates with a postmenstrual age of 34+0 to 44+0 weeks admitted to participating neonatal intensive care units (NICUs) for at least 48 hours at the time of assessment. Participants undergo delirium assessment using the Cornell Assessment of Pediatric Delirium (CAPD) as part of an international multicenter observational point prevalence study.

06

What researchers measure

Primary outcomes

  1. Prevalence of Neonatal Delirium

    Proportion of eligible neonates classified as delirium-positive, defined as at least one Cornell Assessment of Pediatric Delirium (CAPD) score ≥9 on the study day.

    Time frame: Study day (March 10, April 7, or May 5, 2027)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Only aggregated data will be entered into the study database. No patient-identifiable information or individual participant-level data will be transferred between participating sites or entered into the central database.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Apr 2027, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Mar 10, 2027
Primary completionEst.
Apr 7, 2027
CompletionEst.
May 5, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 2 updates
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: criteria formatting
  2. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941245
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Responsible party
Rikke Louise Stenkjær (Principal Investigator, Copenhagen University Hospital, Rigshospitalet) — Principal investigator
First posted
Nov 17, 2026
Start date
Mar 10, 2027 (estimated)
Primary completion
Apr 7, 2027 (estimated)
Completion
May 5, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Rikke L Stenkjaer, RN, PhD
Contact
rikke.louise.stenkjaer@regionh.dk
+45 28358474
Rikke L Stenkjaer, RN, PhD
principal investigator · Copenhagen University Hospital, Rigshospitalet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion